Login to your account

Username *
Password *
Remember Me

Blog With Right Sidebar

    Vous êtes ici :  
  1. Accueil
  2. Blog With Right Sidebar

A Wireless Portable System With Microsensors for Monitoring Respiratory Diseases

A wireless portable monitoring system for respiratory diseases using microsensors is proposed. The monitoring system consists of two sensor nodes integrating with Bluetooth transmitters that measure user's respiratory airflow, blood oxygen saturation, and body posture. The utility of micro-hot-film flow sensor makes the monitor can acquire comprehensive respiration parameters which are useful for diagnoses of obstructive sleep apnea, chronic obstructive pulmonary disease, and asthma. The system can serve as both sleep recorder and spirometer. Additionally, a mobile phone or a PC connected to the Internet serving as a monitoring and transfer terminal makes telemedicine achievable. Several experiments were conducted to verify the feasibility and effectiveness of the proposed system fo...

Particle Deposition in Airways of Chronic Respiratory Patients Exposed to an Urban Aerosol

Environmental Science & TechnologyDOI: 10.1021/es302755s (Source: Environmental Science and Technology)

Influenza A viruses dual and multiple infections with other respiratory viruses and risk of hospitalisation and mortality

Conclusion  Co‐infection is a significant predictor of disease outcome; combined treatment, introduction of an integrated vaccine for all respiratory viruses and development of multi‐target rapid diagnostic tests is recommended. Integration of respiratory viruses’ co‐infections into public health reports could also contribute to the accumulation of evidence. (Source: Influenza and Other Respiratory Viruses)

House dust protein worsens allergic asthma symptoms

A bacterial protein found in common house dust may worsen a person’s asthmatic response to other indoor allergens, say researchers. (Source: MedWire News - Respiratory)

Traitement des récidives de tuberculose pulmonaire

Publication year: 2012
Source:Revue de Pneumologie Clinique, Volume 68, Issue 4

J. Ben Amar, H. Racil, M. Mami, S. Cheikh Rouhou, M. Zarrouk, A. Chabbou

Introduction La tuberculose (TB) sévit à l’état endémique dans le monde. Elle est préoccupante, étant donné les difficultés de sa prise en charge et sa mortalité élevée. Cela nous a amené à analyser la prise en charge thérapeutique et l’évolution des patients ayant eu au moins une récidive tuberculeuse. Patients et méthode Étude rétrospective à partir des dossiers de 64 patients, analysés lors de la première atteinte tuberculeuse (groupe A1) et au moment de la récidive (groupe A2). Le groupe témoin (T) est constitué de patients ayant eu une TB confirmée, sans notion de récidives. Résultats L’étude des données de l’antibiogramme a montré que le taux de multirésistance était plus important en cas de récidive (21,1 % vs 3 %, p <0,05), ainsi que le taux de polyrésistance. La durée moyenne du traitement pour les groupes A1, A2 et T était de 8,63 mois, 9,79 mois et 7,08 mois. Les effets indésirables liés au traitement étaient significativement plus fréquents chez le groupe A2 comparé au groupe T (76,1 % vs 41,2 % ; p <0,001). Conclusion Tout patient tuberculeux, notamment en cas de récidive tuberculeuse, doit bénéficier d’une prise en charge particulière avec un schéma thérapeutique adapté. Introduction Tuberculosis (TB) is a greatest public health problem of the world. This work aims to study the antituberculous treatment and the evolution of the patients with recurrent tuberculosis. Patients and method The study is a retrospective study on 64 patients with recidivant pulmonary TB: A1 group: at the first TB attack; A2 group: at the time of recidivant TB, and 105 controls patients with confirmed TB without recidive. Results Multidrug-resistant TB is more frequent with recidivant TB (21.1% vs 3%, P <0.05) and also extensively drug-resistant. Antituberculous treatment duration in group A1, A2 and T was respectively 8.63 months, 9.79 months, and 7.08 months. Antituberculous drug complications were more frequent in group A2 compared to group T (76.1% vs 41.2%; P <0.001). Conclusion All tuberculous patients, specially recidivant TB, should benefit of particular care and drug protocol adaptation.




Search

Search